ライフサイエンスコーパス: FTC

1 FTC resistance among those initiating PrEP with acute in

2 FTC/TDF showed greater declines in fasting low-density l

3 FTCs and constant freezing shifted nematode body size di

4 FTCs reduced both bacterial and nematode abundance, but

5 In 498 participants (247 FTC/TDF, 251 placebo), BMD in those randomized to FTC/TD

6 3TC/FTC-resistant mutants (M184V/I) emerged infrequently (7/

7 pporting the use of coformulated TDF and 3TC/FTC as preferred backbone drugs for PEP.

8 No effect of prior or concomitant 3TC/FTC was shown.

9 Low-frequency NVP- or 3TC/FTC-resistant mutants at codons 103, 181, and 184 were s

10 Prior treatment with 3TC/FTC does not compromise efficacy of TDF treatment.

11 The use of combination treatment with 3TC/FTC offers no significant benefit over TDF alone.

12 on with SHIVK65R (P = .028), although 4 of 6 FTC/TDF-treated macaques were infected at the end of the

13 15% (18/117) normal subjects vs. 1.3% (1/77) FTC patients, with an odds ratio of 0.07 (95% CI 0.01-0.

14 non that rs17849071G/T is protective against FTC possibly through preventing PIK3CA amplifications.

15 ors, but Pol gamma discriminates against (-)-FTC-TP by two orders of magnitude better than (-)-3TC-TP

16 Furthermore, although (-)-FTC-TP is only slightly more potent against HIV RT than

17 nd by plasma concentrations of tenofovir and FTC at week 4); and safety (clinical and laboratory adve

18 lambda-DNA-D-dCTP, L-dCTP, (-)3TC-TP, and (-)FTC-TP all have their ribose rotated by 180 degrees .

19 test, which did not differ between the arms (FTC/TDF vs placebo, P = .81).

20 2 vs placebo]), and 8.8 among those assigned FTC+TDF (incidence difference, -1.3; 95% CI, -4.1 to 1.5

21 from this pilot study suggest that baseline FTC and changes early in treatment each have utility as

22 have been discovered, i.e., fumitremorgin C (FTC), Ko143, and the alkaloid harmine, which contain a t

23 EVG/c/FTC/TDF led to greater decreases in sCD14, hsCRP, and Lp

24 Significant differences favoring EVG/c/FTC/TDF were noted for changes in sCD14, hsCRP, and Lp-P

25 itabine/tenofovir disoproxil fumarate (EVG/c/FTC/TDF) with that of efavirenz/emtricitabine/tenofovir

26 included random assignment to receive EVG/c/FTC/TDF, higher baseline sCD14 level, and larger decreas

27 in patients with follicular thyroid cancer (FTC).

28 varian cancer (OC) or fallopian tube cancer (FTC).

29 led, and 708 were treated (353 with EVG/COBI/FTC/TDF and 355 with ATV/RTV+FTC/TDF).

30 on increased more by week 48 in the EVG/COBI/FTC/TDF group than in the EFV/FTC/TDF group (median 13 m

31 randomly assigned (1:1) to receive EVG/COBI/FTC/TDF or ATV/RTV+FTC/TDF plus matching placebos, admin

32 e of four in a 1:1 ratio to receive EVG/COBI/FTC/TDF or EFV/FTC/TDF, once daily, plus matching placeb

33 Nausea was more common with EVG/COBI/FTC/TDF than with EFV/FTC/TDF (72/348 vs 48/352) and diz

34 EVG/COBI/FTC/TDF was non-inferior to EFV/FTC/TDF; 305/348 (87.6%)

35 compared the efficacy and safety of EVG/COBI/FTC/TDF with standard of care-co-formulated efavirenz (E

36 N: If regulatory approval is given, EVG/COBI/FTC/TDF would be the first integrase-inhibitor-based reg

37 N: If regulatory approval is given, EVG/COBI/FTC/TDF would be the only single-tablet, once-daily, int

38 Daily oral TDF (n = 598), combination FTC+TDF (n = 566), or placebo (n = 621) through July 201

39 receiving PrEP with TDF alone or combination FTC+TDF compared with placebo at conception.

40 Lower frontal theta cordance (FTC) at baseline (and higher FTC after 4 weeks) predicte

41 f receiving New Zealand's Family Tax Credit (FTC) and self-rated health (SRH) in 6,900 working-age pa

42 in increased warming and freeze-thaw cycle (FTC) frequency pose great ecological challenges to organ

43 ave sex with men (MSM) to receive oral daily FTC/TDF or placebo.

44 BS TFV-DP (r = 0.74; P < .001); hair FTC/DBS FTC-TP (r = 0.587; P < .001).

45 ATV+DDI+FTC and EFV+FTC-TDF were hypothesized to be non-inferior

46 us didanosine-EC plus emtricitabine (ATV+DDI+FTC), or efavirenz plus emtricitabine-tenofovir-disoprox

47 andard of care-co-formulated efavirenz (EFV)/FTC/TDF-as initial treatment for HIV infection.

48 EFV+FTC-TDF had similar high efficacy compared to EFV+3TC-ZD

49 ATV+DDI+FTC and EFV+FTC-TDF were hypothesized to be non-inferior to EFV+3TC-

50 Comparing EFV+FTC-TDF to EFV+3TC-ZDV, during a median 184 wk of follow

51 bine-tenofovir-disoproxil fumarate (DF) (EFV+FTC-TDF).

52 infected women, and once-daily dosing of EFV+FTC-TDF are advantageous for use of this regimen for ini

53 icitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF).

54 1:1 ratio to receive EVG/COBI/FTC/TDF or EFV/FTC/TDF, once daily, plus matching placebo.

55 n the EVG/COBI/FTC/TDF group than in the EFV/FTC/TDF group (median 13 mumol/L, IQR 5 to 20 vs 1 mumol

56 EVG/COBI/FTC/TDF was non-inferior to EFV/FTC/TDF; 305/348 (87.6%) versus 296/352 (84.1%) of patie

57 e common with EVG/COBI/FTC/TDF than with EFV/FTC/TDF (72/348 vs 48/352) and dizziness (23/348 vs 86/3

58 hsCRP, and Lp-PLA2 levels, compared with EFV/FTC/TDF.

59 k 72 had the option of adding emtricitabine (FTC).

60 disoproxil fumarate (TDF) and emtricitabine (FTC) (Complera((R))) and an extended release version of

61 er the combination of TAF and emtricitabine (FTC) could prevent simian/human immunodeficiency virus (

62 disoproxil fumarate (TDF) and emtricitabine (FTC) or placebo before and after sexual activity.

63 enofovir difumarate (TDF) and emtricitabine (FTC), the quad pill includes cobicistat (COBI; an inacti

64 inhibitor cobicistat (COBI), emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF) in a singl

65 inhibitor cobicistat (COBI), emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF) into a onc

66 ce and safety of coformulated emtricitabine (FTC), rilpivirine (RPV), and tenofovir disoproxil fumara

67 < .001), as were hair TFV/DBS emtricitabine (FTC) triphosphate (TP) (r = 0.781; P < .001); hair FTC/D

68 MVC only, MVC-emtricitabine (FTC), MVC-tenofovir disoproxil fumarate (TDF), and TDF-F

69 ulated with the lipid-neutral emtricitabine (FTC), has a lipid-lowering effect.

70 n = 141) or a combination of emtricitabine (FTC, 200 mg; n = 139) and TDF (300 mg, FTC/TDF).

71 1), while lamivudine (LAM) or emtricitabine (FTC) use remained steady (71.9%) and tenofovir (TDF) use

72 prophylactic efficacy of oral emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF).

73 regimens: MVC alone, MVC plus emtricitabine (FTC), MVC plus tenofovir disoproxil fumarate (TDF), and

74 abel ART with tenofovir (TDF)/emtricitabine (FTC) once/day plus either NVP (n = 249) or LPV/r (n = 25

75 In a study of daily TDF/emtricitabine (FTC) preexposure prophylaxis (PrEP) in human immunodefic

76 fovir (TDF), coformulated TDF/emtricitabine (FTC), or placebo.

77 e/lamivudine (3TC), tenofovir/emtricitabine (FTC), or lopinavir/ritonavir for either 7 or 21 days.

78 daily oral TDF, alone or with emtricitabine (FTC), in HIV-uninfected African men and women.

79 vir (ATV) in combination with emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) in treatment-na

80 alone or in combination with emtricitabine (FTC-TDF) reduces the risk for HIV-1 acquisition.

81 (TDF), alone or combined with emtricitabine (FTC-TDF), compared with placebo.

82 lamivudine ((-)3TC-TP) and emtricitabine ((-)FTC-TP) provide little structural evidence to suggest th

83 lamivudine ((-)3TC-TP) and emtricitabine ((-)FTC-TP) with four ternary complexes per asymmetric unit.

84 lamivudine ((-)3TC-TP) and emtricitabine ((-)FTC-TP), we structurally reveal the correct sequence of

85 r the TDF-based regimens (TDF+emtricitabine [FTC]+lopinavir/ritonavir [LPV/r], 71.1%; 95% CI, 43.6%-9

86 omen on ART (tenofovir [TFV], emtricitabine [FTC], and ritonavir-boosted atazanavir [ATV]) with suppr

87 f treatment with TDF (n552) or emtricitabine(FTC)/TDF (n57).

88 otent against HIV RT than its enantiomer (+)-FTC-TP, it is discriminated by human Pol gamma four orde

89 Biodistribution studies showed that (18)F-FTC-146 accumulated in S1R-rich rat organs, including th

90 ministration, significantly attenuated (18)F-FTC-146 accumulation in all rat brain regions by approxi

91 gested radioligand metabolism, whereas (18)F-FTC-146 appeared to be stable in human serum.

92 The potential of (18)F-FTC-146 as an imaging agent for a variety of neuroinflam

93 ain information about the potential of (18)F-FTC-146 for eventual clinical translation.

94 liver microsome studies revealed that (18)F-FTC-146 has a longer half-life in human microsomes, comp

95 y results demonstrated accumulation of (18)F-FTC-146 in rat brain regions known to contain S1Rs and t

96 The distribution and stability of (18)F-FTC-146 in rats were assessed via PET/CT, autoradiograph

97 tudy was to assess the S1R radiotracer (18)F-FTC-146 in rats.

98 demonstrated specific accumulation of (18)F-FTC-146 in the brain (mainly in cortical structures, cer

99 Ex vivo analysis of (18)F-FTC-146 in the brain showed that only intact radiotracer

100 Together, these results indicate that (18)F-FTC-146 is a promising tool for visualizing S1Rs in prec

101 Injection of (18)F-FTC-146 is safe, and absorbed doses are acceptable.

102 onducted along with HPLC assessment of (18)F-FTC-146 stability in monkey plasma and human serum.

103 , whereas rapid metabolism of residual (18)F-FTC-146 was observed in rat plasma.

104 High accumulation of (18)F-FTC-146 was observed in sigma-1 receptor-dense organs su

105 tion well, and no adverse reactions to (18)F-FTC-146 were reported.

106 t-in-human studies with clinical-grade (18)F-FTC-146 were successful.

107 -1-yl)ethyl)benzo[d]thiazol-2(3H)-one ((18)F-FTC-146).

108 1-yl)ethyl)benzo[d]thiazol-2(3H)-one ([(18)F]FTC-146, [(18)F]13).

109 y loss (52 of 143 pregnancies) was 37.5% for FTC+TDF and 36.7% for TDF alone (difference, 0.8%; 95% C

110 e, the frequency of tubulopathy was 1.7% for FTC-TDF versus 1.3% for placebo (odds ratio, 1.30; 95% c

111 for those receiving placebo (difference for FTC+TDF vs placebo, 10.2%; 95% CI, -5.3% to 25.7%; P = .

112 oviral concentration ratios were highest for FTC (11.9, 95% confidence interval [CI], 8.66-16.3), the

113 This represents a 93% risk reduction for FTC with this SNP.

114 udy arms (7.8 cases per 100 person-years for FTC/TDF vs 6.8 cases per 100 person-years for placebo, P

115 Formylthiocholine (FTC) was synthesized and found to be a substrate for non

116 emtricitabine/tenofovir disoproxil fumarate (FTC+TDF), is efficacious for prevention of human immunod

117 icitabine and tenofovir disoproxil fumarate (FTC/TDF) as preexposure prophylaxis (PrEP) protects agai

118 icitabine and tenofovir disoproxil fumarate (FTC/TDF) decreases the risk of human immunodeficiency vi

119 emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) is a novel strategy for preventing human immuno

120 emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) is a preferred nucleoside reverse transcriptase

121 citabine plus tenofovir disoproxil fumarate (FTC/TDF) or TDF alone reduces the risk of human immunode

122 oral emtricitabine/TFV disoproxil fumarate (FTC/TDF).

123 ir FTC/DBS TFV-DP (r = 0.74; P < .001); hair FTC/DBS FTC-TP (r = 0.587; P < .001).

124 riphosphate (TP) (r = 0.781; P < .001); hair FTC/DBS TFV-DP (r = 0.74; P < .001); hair FTC/DBS FTC-TP

125 theta cordance (FTC) at baseline (and higher FTC after 4 weeks) predicted lower depression severity s

126 added emtricitabine 200 mg/tenofovir 300 mg (FTC/TDF) once daily.

127 bine (FTC, 200 mg; n = 139) and TDF (300 mg, FTC/TDF).

128 adverse events occurred in 5 (MVC), 13 (MVC-FTC), 9 (MVC-TDF), and 8 (TDF-FTC) participants; rates d

129 value, and negative predictive value for OC/FTC detection within 1 year were 94.7% (CI, 74.0% to 99.

130 the total 19 diagnoses were stage I to II OC/FTC (CI, 28.9% to 75.6%).

131 Sensitivity for detection of incident OC/FTC at 1 year after last annual screen was 81.3% (95% CI

132 n of 88 days before detection of incident OC/FTC.

133 ion was 79 days in prevalent and incident OC/FTC.

134 een patients were diagnosed with invasive OC/FTC within 1 year of prior screening (13 diagnoses were

135 ds Women whose estimated lifetime risk of OC/FTC was >/= 10% were recruited at 42 centers in the Unit

136 at an estimated >/= 10% lifetime risk of OC/FTC were recruited and screened by 37 centers in the Uni

137 ng is an option for women at high risk of OC/FTC who defer or decline RRSO, given its high sensitivit

138 ur (30.8%) of 13 incident screen-detected OC/FTCs were stage I or II.

139 nded to rebound following discontinuation of FTC/TDF.

140 Six macaques received weekly a dose of FTC/TDF 3 days before rectal SHIV exposures and a second

141 We report the effect of FTC/TDF on BMD in HIV-seronegative men who have sex with

142 The effect of FTC/TDF on incident syphilis and HIV acquisition was ass

143 esults support the clinical investigation of FTC/TAF for PrEP.

144 xchange of (18)O into the carbonyl oxygen of FTC or the product, formate, under any of the above cond

145 A single-tablet regimen of FTC-RPV-TDF was well tolerated as once-daily PEP, with h

146 d, double-blind, placebo-controlled trial of FTC/TDF PrEP.

147 Within the largest randomized trial of FTC/TDF versus TDF as PrEP, plasma samples were tested f

148 We predict that higher occurrence of FTCs in cold ecosystems will select for large body size

149 , this work illuminates the mechanism of (-)-FTC-TP differential selectivity and provides a structura

150 o baseline (23/52 [44%] on TDF, 4/7 [57%] on FTC/TDF).

151 Fewer subjects on FTC/TDF experienced VF (3 vs 11; P = .034).

152 rettes smoked under ISO (Cambridge Filter or FTC) and Intense (Health Canada or Canadian Intense) con

153 k for up to 16 weeks and received placebo or FTC/TDF pericoitally.

154 ek for up to 19 weeks and received saline or FTC/TAF 24 hours before and 2 hours after each virus ino

155 o HSV-2 (79 of 1041 assigned to tenofovir or FTC-TDF PrEP [HSV-2 incidence, 5.6 per 100 person-years]

156 Oral FTC/TDF maintains efficacy in a macaque model of sexuall

157 Daily oral FTC-TDF PrEP was not significantly associated with tubul

158 ilar for the intermittent gel and daily oral FTC/TDF regimens, but lower for the daily gel regimen.

159 eekly in the event of no RAI), or daily oral FTC/TDF.

160 ic mechanism in thyroid cancer, particularly FTC.

161 In HIV-uninfected persons, FTC/TDF PrEP was associated with small but statistically

162 inferior to RTV in combination with ATV plus FTC/TDF at week 48.

163 ovir disoproxil fumarate (TDF), and TDF plus FTC.

164 Of 121 HIV seroconverters, 25 received FTC/TDF, 38 received TDF, and 58 received placebo.

165 Of 1549 persons studied (776 receiving FTC-TDF, 773 receiving placebo), 64% were male, and the

166 8 pregnancies) was 42.5% for women receiving FTC+TDF compared with 32.3% for those receiving placebo

167 As a result, (-)-FTC is a much less toxic NRTI.

168 ere treated in this study (155 to PI + RTV + FTC/TDF, 156 to PI + RTV + 3TC/ABC).

169 (1:1) to receive EVG/COBI/FTC/TDF or ATV/RTV+FTC/TDF plus matching placebos, administered once daily.

170 3 with EVG/COBI/FTC/TDF and 355 with ATV/RTV+FTC/TDF).

171 nfections randomized to FTC/TDF, none showed FTC/TDF mutations by clinical assays despite detectable

172 Drug resistance was rare in iPrEx on-study FTC/TDF-randomized seroconverters, and only as low-frequ

173 requiring 3-drug PEP received single-tablet FTC-RPV-TDF once daily for 28 days.

174 safe and well tolerated compared with TDF + FTC; this study was not powered for efficacy.

175 gravir [RAL], 74.7%; 95% CI, 41.4%-100%; TDF+FTC+ boosted darunavir [DRV/r], 93.9%; 95% CI, 90.2%-97.

176 vir [LPV/r], 71.1%; 95% CI, 43.6%-98.6%; TDF+FTC+raltegravir [RAL], 74.7%; 95% CI, 41.4%-100%; TDF+FT

177 o adverse drug reactions were lowest for TDF+FTC+RAL (1.9%; 95% CI, 0%-3.8%) and highest for ZDV+3TC+

178 [41.7%]; ARR, 1.15; 95% CI, 1.04-1.27); TDF-FTC and lopinavir-ritonavir (TDF-FTC-LPV-R) (112 of 231

179 (MVC), 13 (MVC-FTC), 9 (MVC-TDF), and 8 (TDF-FTC) participants; rates did not differ among regimens.

180 tenofovir disoproxil fumarate (TDF), and TDF-FTC (control).

181 Oral TDF and TDF-FTC both protect against HIV-1 infection in heterosexual

182 infants exposed to ART from conception, TDF-FTC-EFV was associated with a lower risk for adverse bir

183 Daily TDF-FTC prophylaxis prevented HIV infection in sexually acti

184 The long-term safety of daily TDF-FTC prophylaxis, including the effect on bone mineral de

185 fumarate, emtricitabine, and efavirenz (TDF-FTC-EFV) (901 of 2472 [36.4%]) compared with TDF-FTC and

186 in the DTG-ABC-3TC group than in the EFV-TDF-FTC group (2% vs. 10%); rash and neuropsychiatric events

187 me to viral suppression than did the EFV-TDF-FTC group (28 vs. 84 days, P<0.001), as well as greater

188 in the DTG-ABC-3TC group than in the EFV-TDF-FTC group (88% vs. 81%, P=0.003), thus meeting the crite

189 arate (DF)-emtricitabine once daily (EFV-TDF-FTC group).

190 ere significantly more common in the EFV-TDF-FTC group, whereas insomnia was reported more frequently

191 ipants with virologic failure in the EFV-TDF-FTC group.

192 r disoproxil fumarate and emtricitabine (TDF-FTC) for preexposure prophylaxis (PrEP) is an effective

193 r disoproxil fumarate and emtricitabine (TDF-FTC) or matching placebo once daily.

194 r disoproxil fumarate and emtricitabine (TDF-FTC) or placebo once daily.

195 ate (TDF), oral tenofovir-emtricitabine (TDF-FTC), or 1% tenofovir (TFV) vaginal gel as preexposure p

196 F), combination tenofovir-emtricitabine (TDF-FTC), or matching placebo--and followed monthly for up t

197 Protective effects of TDF-FTC and TDF alone against HIV-1 were not significantly d

198 The use of TDF-FTC before and after sexual activity provided protection

199 ctive was to assess the effectiveness of TDF-FTC in preventing HIV acquisition and to evaluate safety

200 articipants took a median of 15 pills of TDF-FTC or placebo per month (P=0.57).

201 on-years, respectively), the efficacy of TDF-FTC was 62.2% (95% confidence interval, 21.5 to 83.4; P=

202 ipants randomly assigned to receive oral TDF-FTC than among those assigned to receive oral placebo (1

203 in the proportion of persons prescribed TDF-FTC for PrEP during the study period, with 417 users in

204 ons aged >/=16 years who were prescribed TDF-FTC for PrEP each year.

205 Participants who received TDF-FTC, as compared with those who received placebo, had a

206 -1.27); TDF-FTC and lopinavir-ritonavir (TDF-FTC-LPV-R) (112 of 231 [48.5%]; ARR, 1.31; 95% CI, 1.13-

207 ipants randomly assigned to receive TDF, TDF-FTC, and TFV gel, respectively.

208 V infections occurred in 33 women in the TDF-FTC group (incidence rate, 4.7 per 100 person-years) and

209 ions occurred during follow-up, 2 in the TDF-FTC group (incidence, 0.91 per 100 person-years) and 14

210 levels were significantly higher in the TDF-FTC group (P=0.04, P<0.001, and P=0.03, respectively).

211 HIV infection were enrolled (199 in the TDF-FTC group and 201 in the placebo group).

212 came infected during the study (9 in the TDF-FTC group and 24 in the placebo group; 1.2 and 3.1 infec

213 n 40% of the HIV-uninfected women in the TDF-FTC group had evidence of recent pill use at visits that

214 The TDF-FTC group had higher rates of nausea (18.5% vs. 7.1%, P<

215 s), for an estimated hazard ratio in the TDF-FTC group of 0.94 (95% confidence interval, 0.59 to 1.52

216 rson-years), a relative reduction in the TDF-FTC group of 86% (95% confidence interval, 40 to 98; P=0

217 ations developed in 1 participant in the TDF-FTC group who had had an unrecognized acute HIV infectio

218 In the TDF-FTC group, as compared with the placebo group, there wer

219 : 1584 randomly assigned to TDF, 1579 to TDF-FTC, and 1584 to placebo.

220 interval [CI], 0.97 to 2.29), -4.4% with TDF-FTC (hazard ratio, 1.04; 95% CI, 0.73 to 1.49), and 14.5

221 EFV) (901 of 2472 [36.4%]) compared with TDF-FTC and nevirapine (NVP) (317 of 760 [41.7%]; ARR, 1.15;

222 re safe and well-tolerated compared with TDF-FTC in U.S. women.

223 Compared with TDF-FTC-EFV, all other regimens were associated with higher

224 TDF/FTC/EFV was equivalent or superior to its comparator arm

225 TDF/FTC/NVP was either equivalent or inferior to its compara

226 In arm 1, TDF/FTC was added for 12 weeks, followed by 12 weeks of plac

227 tion (TDF HR = 0.18, 95% CI: 0.06, 0.53; TDF/FTC HR = 0.15, 95% CI: 0.04, 0.52); and 3) in per-protoc

228 ysis (TDF HR = 0.18, 95% CI: 0.06, 0.53; TDF/FTC HR = 0.16, 95% CI: 0.05, 0.53).

229 5% confidence interval (CI): 0.07, 0.56; TDF/FTC HR = 0.12, 95% CI: 0.03, 0.52); 2) with IPC weights

230 in a behavioral intervention and accept TDF/FTC as PrEP.

231 content decreased within the ABC/3TC and TDF/FTC groups (combining EFV and ATV/r arms; median change,

232 Differences between the ABC/3TC and TDF/FTC groups were significant for complex I (P = .03).

233 ABC/3TC and TDF/FTC significantly and similarly decreased fat mtDNA cont

234 of participants enrolled in the Botswana TDF/FTC Oral HIV Prophylaxis Trial, the Bangkok Tenofovir St

235 or 12 weeks (placebo period) followed by TDF/FTC for 12 weeks and placebo for 12 additional weeks (wa

236 Coformulated TDF/FTC has an intrinsic lipid-lowering effect, likely attri

237 ntervention and were provided with daily TDF/FTC as PrEP for 48 weeks.

238 posure prophylaxis]) of 30 days of daily TDF/FTC followed by 30 days off drug were evaluated.

239 r NNRTI and a backbone containing either TDF/FTC or ABC/3TC.

240 fovir disoproxil fumarate/emtricitabine (TDF/FTC) doses required to achieve and maintain (after disco

241 fovir disoproxil fumarate/emtricitabine (TDF/FTC) for PrEP is only licensed for adults.

242 ne (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC) in 1857 human immunodeficiency virus type 1-infecte

243 h a backbone of tenofovir/emtricitabine (TDF/FTC) or abacavir/lamivudine (ABC/3TC).

244 e randomized to tenofovir-emtricitabine (TDF/FTC) plus atazanavir-ritonavir (ATV/r), darunavir-ritona

245 fovir disoproxil fumarate/emtricitabine (TDF/FTC) plus atazanavir/ritonavir (ATV/r), darunavir/ritona

246 fovir disoproxil fumarate-emtricitabine (TDF/FTC) plus atazanavir/ritonavir (ATV/r), darunavir/ritona

247 /3TC) versus tenofovir DF-emtricitabine (TDF/FTC) with efavirenz (EFV) or atazanavir-ritonavir (ATV/r

248 acy estimates of 67% for TDF and 75% for TDF/FTC.

249 ervention in conjunction with open-label TDF/FTC.

250 Initial ART with NVP+TDF/FTC demonstrated equivalent virologic efficacy but highe

251 fety, tolerability, and acceptability of TDF/FTC and patterns of use, rates of adherence, and pattern

252 s support the short-term renal safety of TDF/FTC PrEP in HIV-seronegative young men and suggest that

253 A backbone of TDF/FTC was received by 67% of PI users and 69% of NNRTI use

254 ly decreased fat mtDNA content, but only TDF/FTC decreased complex I and complex IV activity levels.

255 new drug resistance compared with LPV/r+TDF/FTC in antiretroviral-naive women with CD4<200 cells/mm(

256 provide additional safety data regarding TDF/FTC use among young MSM who had negative test results fo

257 activity decreased significantly in the TDF/FTC group (median change, -12.45 [interquartile range, -

258 Exposure to TDF/FTC reduced TC from 234 to 205 mg/dL (P < .001), LDL-c f

259 After 12 weeks, TDF/FTC exposure was associated with lower TC and LDL-c leve

260 triglyceride levels did not change with TDF/FTC exposure.

261 With TDF/FTC use, no clear association was found among PI users (

262 t-naive participants initiating ART with TDF/FTC, no differences in lean mass and regional fat were f

263 (32%) safety risk compared to men; with TDF/FTC, the safety risk was 20% larger for women compared t

264 ) trial and whether emtricitabine/tenofovir (FTC/TDF) modified that association.

265 Hair TFV/FTC concentrations correlate strongly with DBS levels, w

266 rders of magnitude more efficiently than (+)-FTC-TP.

267 and in PrEP breakthrough infections and that FTC is associated with a greater frequency of resistance

268 fection, resistance was more frequent in the FTC/TDF arm (4 of 7 [57%]), compared with the TDF arm (1

269 d in both arms with a larger decrease in the FTC/TDF arm.

270 f patients in the TDF group and 86.3% in the FTC/TDF group had levels of HBV DNA <69 IU/mL (P = .43).

271 between groups; only 1 patient (0.7%) in the FTC/TDF group lost hepatitis B surface antigen.

272 Of all participants, 5.1%-6.8% received the FTC for 1-3 years and 1.8%-3.6% for 4-7 years.

273 Cumulatively receiving the FTC marginally reduced SRH.

274 lyses, each additional year of receiving the FTC was associated with 0.033 (95% confidence interval (

275 arm (1 of 19 [5.3%]; P = .01), owing to the FTC-associated mutation M184IV.

276 for interaction between randomization to the FTC/TDF arm and incident syphilis on HIV incidence.

277 )-2,3'-dideoxy-5-fluoro-3'-thiacytidine, (-)-FTC] and lamivudine, [(-)-2,3'-dideoxy-3'-thiacytidine,

278 daily gel use for HIV protection compared to FTC/TDF (OR, 0.38; P < .001).

279 or RAI gel (IRR, 0.90; P = .51) compared to FTC/TDF.

280 ose with acute infection at randomization to FTC/TDF, M184V or I mutations that were predominant at s

281 DF, 251 placebo), BMD in those randomized to FTC/TDF decreased modestly but statistically significant

282 Two randomized to FTC/TDF had minor variant M184I detected at 0.53% by AS-

283 Of the 48 on-study infections randomized to FTC/TDF, none showed FTC/TDF mutations by clinical assay

284 h was detected in 53% of those randomized to FTC/TDF.

285 were measured in participants randomized to FTC/TDF.

286 randomized to continue 3TC/ABC or switch to FTC/TDF.

287 57 patients (10%)were eligible to switch to FTC/TDF; the majority had HBV DNA <400 copies/mL at thei

288 visit regardless of whether they switched to FTC/TDF (n534) or maintained TDF monotherapy (n517).

289 3TC/ABC regimen, the merits of switching to FTC/TDF as the NRTI backbone are unknown.

290 Switching to FTC/TDF from 3TC/ABC maintained virologic suppression, h

291 Switching to FTC/TDF showed improved NCEP thresholds for TC and TG an

292 By TLOVR through week 48, switching to FTC/TDF was noninferior compared to continued 3TC/ABC (8

293 evaluate efficacy and safety of switching to FTC/TDF.

294 We investigated in macaques whether FTC/TDF prevents transmission of a tenofovir-resistant s

295 IV with resistance mutations associated with FTC (K65R and M184IV) and TDF (K65R and K70E), using 454

296 0%-85% maintained levels <400 copies/mL with FTC/TDF intensification as needed.

297 eciprocal relationship of rs17849071G/T with FTC, since PIK3CA amplification is an important oncogeni

298 Minor variants with FTC/TDF mutations K65R, K70E, M184V/I were measured usin

299 LPV/r monotherapy after first-line VF with FTC/TDF intensification when needed provides durable sup

300 In contrast, warm temperatures without FTCs could lead to divergent responses in soil bacteria